histamine and Pemphigoid

histamine has been researched along with Pemphigoid in 4 studies

Research

Studies (4)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Decrease in Anti-BP180 IgG (Immunoglobulin G Anti-Bullous Pemphigoid 180 Antibody) Following Treatment With Omalizumab.

Anti-BP180 IgG levels were completed using an Elisa assay. Anti-BP180 IgG levels were obtained prior to baseline and at week 16 (NCT00472030)
Timeframe: Up to 24 weeks

Decrease in Anti-BP230 Antibody IgG (Anti-bullous Pemphigoid 230 Antibody Immunoglobulin G) At Baseline and Week 16

(NCT00472030)
Timeframe: Up to 24 weeks

Decrease in Eosinophil Levels Following Treatment With Omalizumab.

The subject's eosinophil count measured at baseline was compared to the eosinophil count at week 8. A normal eosinophil count at the University of Iowa Hospital lab is 0-0.4 cells per microliter (NCT00472030)
Timeframe: Baseline, 24 weeks.

Median Time From First Dose of Omalizumab Treatment to Cessation of New Blisters.

The study subject underwent physical examination and was assessed for cessation of new blister formation via physical examination and photography. (NCT00472030)
Timeframe: Up to 24 weeks

Percent Decrease in the Total Body Surface Area Affected By Active Bullous Pemphigoid Skin Disease From Day 0 to Week 24.

Measurement of total body surface area affected by bullous pemphigoid active skin disease(active erosions, blisters, and/or lesions) was measured at Day 0 (prior to treatment with Omalizumab) and at 24 weeks (24 weeks is end of study). (NCT00472030)
Timeframe: Up to 24 weeks

Other Studies

4 other studies available for histamine and Pemphigoid